Doseloop Beta

Spironolactone

medication Under review

A potassium-sparing diuretic medication used to treat fluid retention, high blood pressure, and various hormonal conditions.

Research summary

AI-Generated Content: This summary was created by AI and may contain errors. Always verify with peer-reviewed sources.

Human research on spironolactone is extensive for approved cardiovascular indications, but in healthy or relatively healthy populations the most relevant evidence concerns off‑label dermatologic use and emerging neuropsychiatric applications. Randomized, placebo‑controlled trials in women with acne vulgaris show that oral spironolactone at doses of 50–100 mg daily improves inflammatory acne lesions and global acne severity with acceptable tolerability, supporting its role as an effective antiandrogenic therapy for female acne. Large observational analyses have also examined spironolactone use in otherwise healthy young women and girls, documenting substantial growth in prescribing over the past two decades, mainly driven by dermatologic indications. An exploratory human study suggests that spironolactone exposure is associated with reduced hazardous alcohol consumption in adults with heavy drinking patterns, raising interest in its potential as a pharmacotherapy for alcohol use disorder. Overall, the research consensus supports spironolactone as a hormone‑modulating drug with clear benefits for certain conditions, but its use is medication‑level rather than a general wellness supplement, and safety considerations such as hyperkalemia, endocrine effects, and potential drug interactions are central.

Reported Benefits

Reported Side Effects

Related health conditions

Research showing how this habit affects specific health conditions. Always consult healthcare professionals.

May Help With

Research (4 studies)

Systematic Review

Oral spironolactone for acne vulgaris in females: a clinical review and evidence synthesis

Journal of the European Academy of Dermatology and Venereology • 2025 • n=200

Thompson A, et al.

Cohort study

Trends in the Proportion of Young Women and Girls Prescribed Spironolactone.

JAMA Network Open • 2023 • n=132000

Dieleman JL, et al.

Cohort study

Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent models and human data

Molecular Psychiatry • 2022 • n=784

Satta R, et al.

Cohort study

Adverse effect profile of spironolactone: a clinical experience in adult patients

American Journal of Medicine • 2007 • n=120

Ahmed A, et al.

Community updates

No updates yet for this supplement.

Be the first to share your experience!

At a glance

Users tracking 0
Linked studies 4
Researched benefits 2
Side effects noted 5